Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories (ABT) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Abbott Laboratories is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pr ...

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.19 per share, indicating an increase of 15.5% compared to the year-ago period. Analysts forecast revenues of $10.17 billion, representing an increase of 0.8% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company ...

Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to target and treat tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tiss ...

Abbott’s (ABT) Established Pharmaceuticals Division (EPD) businesses are expected to grow in the coming quarters, banking on new launches. However, the business environment continues to be challenging globally. The stock carries a Zacks Rank #3 (Hold) currently.Abbott is expanding its Diagnostics business foothold (consisting of 24% of the company’s total revenues in the third quarter of 2023). Over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID ...

Abbott Laboratories (ABT) is slated to report its fourth-quarter 2023 results on Jan 24 before market open.The company posted adjusted earnings per share (EPS) of $1.14 in the last reported quarter, which topped the Zacks Consensus Estimate by 3.64%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all occasions, the average beat being 6.76%.Let's see how things have shaped up prior to this announcement.Factors at PlayEstablished Pharmaceuticals Similar to the last report ...

2024年1月8日至11日，第42届摩根大通医疗健康年会（J.P. Morgan Healthcare Conference，以下简称JPM）在美国加利福尼亚州旧金山隆重召开。JPM大会是全球生物医药健康领域规模最大的行业盛会，也是全球信息量最大的医疗投资、产业交流合作大会，涵盖了整个全球医疗保健领域，包括制药公司、医疗保健服务提供商、营利和非营利组织以及医疗器械公司。 雅培方面，对话摩根大通医疗技术分析师的是公司董事长兼首席执行官Robert Ford。 Robert Ford 业绩概览 Robert表示，雅培有一个野心勃勃的目标，那就是超出自己目前水平的50%，到2030年帮助改善30亿人的生活。雅培的故事源于19世纪末，自那以来，雅培一直在现代医疗领域取得突破性创新，是仅有的49家始终存在于《财富》500强榜单中的公司之一。 目前，雅培在全球的员工超过115,000名，服务于160多个国家。公司以一系列知名的品牌建立了良好形象，这些品牌年销售额超过400亿美元，在过去10年翻了一番。雅培的构成多年来发生了变化，但不变的是雅培致力于为股东带来长期价值的框架。雅培有意在投资组合、不同的地理位置和不同类型的 ...

Abbott (ABT) closed at $113.92 in the latest trading session, marking a +0.37% move from the prior day. This change outpaced the S&P 500's 0.08% gain on the day. Meanwhile, the Dow lost 0.31%, and the Nasdaq, a tech-heavy index, added 0.02%.Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 4.51% over the past month, lagging the Medical sector's gain of 6.57% and outpacing the S&P 500's gain of 3.52% in that time.Market participants will be closely following the ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this maker of infant formula, medical devices and drugs have returned +4.5% over the past month versus the Zacks S&P 500 composite's +3.5% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 5.8% over this period. Now the key question is: Where could the stock be headed in the near ter ...

Abbott (ABT) ended the recent trading session at $112.73, demonstrating a +0.29% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.15%. At the same time, the Dow lost 0.42%, and the tech-heavy Nasdaq gained 0.09%.The maker of infant formula, medical devices and drugs's stock has climbed by 5.82% in the past month, falling short of the Medical sector's gain of 6.58% and outpacing the S&P 500's gain of 3.5%.Investors will be eagerly watching for the performance of ...

Abbott Laboratories (NYSE:ABT) 42nd Annual J.P. Morgan Healthcare Conference Call January 9, 2024 12:00 PM ET Company Participants Robert Ford - Chairman and Chief Executive Officer Conference Call Participants Robert Marcus - JPMorgan Robert Marcus Hi. Thanks, everyone. If we could take a seat and get started here. I'm Robbie Marcus, the Med Tech analyst at JPMorgan. Really happy to introduce our next speaker, Robert Ford, the CEO of Abbott. We'll do a little bit of presentation, then I'll join him up here ...